133046-46-5

Basic information

• Product Name: 4-Thiazolecarboxylicacid,2-(trifluoromethyl)-,ethylester(9CI)
• Synonyms: 4-Thiazolecarboxylicacid,2-(trifluoromethyl)-,ethylester(9CI);4-Thiazolecarboxylicacid,2-(trifluoroMethyl)-,ethylester;2-TrifluoroMethyl-thiazole-4-carboxylic acid ethyl ester;Ethyl 2-(Trifluoromethyl)-1,3-Thiazole-4-Carboxylate
• CAS NO: 133046-46-5
• Molecular Formula: C₇H₆F₃NO₂S
• Molecular Weight: 225.19
• Product Categories: THIAZOLE
• Mol File: 133046-46-5.mol

Chemical Properties

• Boiling Point: 194.8°C at 760 mmHg
• Flash Point: 71.6°C
• Appearance: /
• Density: 1.407g/cm³
• Vapor Pressure: 0.433mmHg at 25°C
• Refractive Index: 1.463
• Storage Temp.: 2-8°C
• PKA: -2.54±0.10(Predicted)
• CAS DataBase Reference: 4-Thiazolecarboxylicacid,2-(trifluoromethyl)-,ethylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Thiazolecarboxylicacid,2-(trifluoromethyl)-,ethylester(9CI)(133046-46-5)
• EPA Substance Registry System: 4-Thiazolecarboxylicacid,2-(trifluoromethyl)-,ethylester(9CI)(133046-46-5)

Safety Data

• Hazardous Substances Data: 133046-46-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Thiazolecarboxylic acid, 2-(trifluoromethyl)-, ethyl ester (9CI) is used as a key intermediate in the synthesis of various medicines and drugs. Its unique chemical structure contributes to the development of pharmaceuticals with specific therapeutic properties.
Used in Agricultural Chemicals Synthesis:
In the agricultural sector, 4-Thiazolecarboxylic acid, 2-(trifluoromethyl)-, ethyl ester (9CI) serves as a building block for the synthesis of agricultural chemicals. Its incorporation into these products enhances their effectiveness in crop protection and management.
Used in Dyes Synthesis:
4-Thiazolecarboxylicacid,2-(trifluoromethyl)-,ethylester(9CI) is also utilized in the synthesis of dyes, where its chemical properties contribute to the creation of vibrant and stable colorants for various applications.
Used in Materials Science:
4-Thiazolecarboxylic acid, 2-(trifluoromethyl)-, ethyl ester (9CI) has potential applications in materials science, where it can be used to develop new materials with specific properties for use in various industries.
Used as a Building Block for Organic Compounds:
4-Thiazolecarboxylicacid,2-(trifluoromethyl)-,ethylester(9CI) also serves as a building block for the development of new organic compounds, further expanding its utility across different industrial applications.

InChI:InChI=1/C7H6F3NO2S/c1-2-13-5(12)4-3-14-6(11-4)7(8,9)10/h3H,2H2,1H3

Upstream product

• 354-38-1 2,2,2-trifluoroacetamide 
• 100367-77-9 ethyl 2-bromothiazole-4-carboxylate 
• 1895006-01-5 dimesityl(trifluoromethyl)sulfonium trifluoromethanesulfonate 
• 19172-47-5 Lawessons reagent 
• 70-23-5 ethyl Bromopyruvate 
• 421-52-3 trifluorothioacetamide 

Downstream Products

• 915030-08-9 2-(trifluoromethyl)thiazole-4-carboxylic acid 
• 133046-48-7 2-(trifluoromethyl)-1,3-thiazole-4-carbaldehyde 
• 133046-47-6 (2-(trifluoromethyl)-1,3-thiazol-4-yl)methanol 

Relevant articles and documents

Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor

Focal adhesion kinase (FAK) is a tyrosine kinase with prominent roles in protein scaffolding, migration, angiogenesis, and anchorage-independent cell survival and is an attractive target for the development of cancer therapeutics. However, current FAK inhibitors display dual kinase inhibition and/or significant activity on several kinases. Although multitargeted activity is at times therapeutically advantageous, such behavior can also lead to toxicity and confound chemical-biology studies. We report a novel series of small molecules based on a tricyclic pyrimidothiazolodiazepinone core that displays both high potency and selectivity for FAK. Structure-activity relationship (SAR) studies explored modifications to the thiazole, diazepinone, and aniline "tail,"which identified lead compound BJG-03-025. BJG-03-025 displays potent biochemical FAK inhibition (IC50 = 20 nM), excellent kinome selectivity, activity in 3D-culture breast and gastric cancer models, and favorable pharmacokinetic properties in mice. BJG-03-025 is a valuable chemical probe for evaluation of FAK-dependent biology.

SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS

Disclosed are compounds that possess inhibitory activity against FAK. Also disclosed are pharmaceutical compositions containing the compounds and methods of using the compounds to treat cancer mediated by aberrant FAK activity.

A radical approach to the copper oxidative addition problem: Trifluoromethylation of bromoarenes

Transition metal–catalyzed arene functionalization has been widely used for molecular synthesis over the past century. In this arena, copper catalysis has long been considered a privileged platform due to the propensity of high-valent copper to undergo reductive elimination with a wide variety of coupling fragments. However, the sluggish nature of oxidative addition has limited copper’s capacity to broadly facilitate haloarene coupling protocols. Here, we demonstrate that this copper oxidative addition problem can be overcome with an aryl radical–capture mechanism, wherein the aryl radical is generated through a silyl radical halogen abstraction. This strategy was applied to a general trifluoromethylation of aryl bromides through dual copper-photoredox catalysis. Mechanistic studies support the formation of an open-shell aryl species.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

PAR4 AGONIST PEPTIDES

The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.

IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula (Ia) or (Ib), pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)

Compounds of formula (I) which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VRl, also known as TRPVl).

2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)

The use of a compound of formula (I): for the manufacture of a medicament for the treatment of conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1, also known as TRPV1).